Radiation therapy dose escalation for prostate cancer: A rationale for IMRT

Alan Pollack, Alex Hanlon, Eric M. Horwitz, Steven Feigenberg, Robert G. Uzzo, Robert A. Price

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The response of prostate cancer to radiation was well-documented in the pre-PSA era. Large palpable tumors resolved within months of treatment with relatively modest radiation doses of 64-70 Gy. The use of PSA-based failure as an endpoint, however, has made it clear that cure rates were much lower than appreciated. While doses in this range are still widely used today, data from retrospective, sequential prospective and now randomized studies indicate that for patients with intermediate-to-high risk disease, doses above 70 Gy are associated with a significant reduction in biochemical failure. The use of 3D-conformal radiotherapy to escalate radiation dose has resulted in modest increases in rectal and bladder toxicity. The application of intensity modulated radiotherapy methods allows for greater sparing of the surrounding normal tissues and, hence, the potential to further escalate dose. The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described.

Original languageEnglish
Pages (from-to)200-208
Number of pages9
JournalWorld Journal of Urology
Volume21
Issue number4
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiotherapy
Radiation
Urinary Bladder
Conformal Radiotherapy
Intensity-Modulated Radiotherapy
Prostate
Neoplasms
Therapeutics

Keywords

  • Dose escalation
  • Intensity modulated radiotherapy
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Pollack, A., Hanlon, A., Horwitz, E. M., Feigenberg, S., Uzzo, R. G., & Price, R. A. (2003). Radiation therapy dose escalation for prostate cancer: A rationale for IMRT. World Journal of Urology, 21(4), 200-208. https://doi.org/10.1007/s00345-003-0356-x

Radiation therapy dose escalation for prostate cancer : A rationale for IMRT. / Pollack, Alan; Hanlon, Alex; Horwitz, Eric M.; Feigenberg, Steven; Uzzo, Robert G.; Price, Robert A.

In: World Journal of Urology, Vol. 21, No. 4, 01.09.2003, p. 200-208.

Research output: Contribution to journalArticle

Pollack, A, Hanlon, A, Horwitz, EM, Feigenberg, S, Uzzo, RG & Price, RA 2003, 'Radiation therapy dose escalation for prostate cancer: A rationale for IMRT', World Journal of Urology, vol. 21, no. 4, pp. 200-208. https://doi.org/10.1007/s00345-003-0356-x
Pollack, Alan ; Hanlon, Alex ; Horwitz, Eric M. ; Feigenberg, Steven ; Uzzo, Robert G. ; Price, Robert A. / Radiation therapy dose escalation for prostate cancer : A rationale for IMRT. In: World Journal of Urology. 2003 ; Vol. 21, No. 4. pp. 200-208.
@article{d47d8435ce22444f90415d69701a04f6,
title = "Radiation therapy dose escalation for prostate cancer: A rationale for IMRT",
abstract = "The response of prostate cancer to radiation was well-documented in the pre-PSA era. Large palpable tumors resolved within months of treatment with relatively modest radiation doses of 64-70 Gy. The use of PSA-based failure as an endpoint, however, has made it clear that cure rates were much lower than appreciated. While doses in this range are still widely used today, data from retrospective, sequential prospective and now randomized studies indicate that for patients with intermediate-to-high risk disease, doses above 70 Gy are associated with a significant reduction in biochemical failure. The use of 3D-conformal radiotherapy to escalate radiation dose has resulted in modest increases in rectal and bladder toxicity. The application of intensity modulated radiotherapy methods allows for greater sparing of the surrounding normal tissues and, hence, the potential to further escalate dose. The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described.",
keywords = "Dose escalation, Intensity modulated radiotherapy, Prostate cancer",
author = "Alan Pollack and Alex Hanlon and Horwitz, {Eric M.} and Steven Feigenberg and Uzzo, {Robert G.} and Price, {Robert A.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1007/s00345-003-0356-x",
language = "English",
volume = "21",
pages = "200--208",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Radiation therapy dose escalation for prostate cancer

T2 - A rationale for IMRT

AU - Pollack, Alan

AU - Hanlon, Alex

AU - Horwitz, Eric M.

AU - Feigenberg, Steven

AU - Uzzo, Robert G.

AU - Price, Robert A.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The response of prostate cancer to radiation was well-documented in the pre-PSA era. Large palpable tumors resolved within months of treatment with relatively modest radiation doses of 64-70 Gy. The use of PSA-based failure as an endpoint, however, has made it clear that cure rates were much lower than appreciated. While doses in this range are still widely used today, data from retrospective, sequential prospective and now randomized studies indicate that for patients with intermediate-to-high risk disease, doses above 70 Gy are associated with a significant reduction in biochemical failure. The use of 3D-conformal radiotherapy to escalate radiation dose has resulted in modest increases in rectal and bladder toxicity. The application of intensity modulated radiotherapy methods allows for greater sparing of the surrounding normal tissues and, hence, the potential to further escalate dose. The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described.

AB - The response of prostate cancer to radiation was well-documented in the pre-PSA era. Large palpable tumors resolved within months of treatment with relatively modest radiation doses of 64-70 Gy. The use of PSA-based failure as an endpoint, however, has made it clear that cure rates were much lower than appreciated. While doses in this range are still widely used today, data from retrospective, sequential prospective and now randomized studies indicate that for patients with intermediate-to-high risk disease, doses above 70 Gy are associated with a significant reduction in biochemical failure. The use of 3D-conformal radiotherapy to escalate radiation dose has resulted in modest increases in rectal and bladder toxicity. The application of intensity modulated radiotherapy methods allows for greater sparing of the surrounding normal tissues and, hence, the potential to further escalate dose. The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described.

KW - Dose escalation

KW - Intensity modulated radiotherapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=1542293746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542293746&partnerID=8YFLogxK

U2 - 10.1007/s00345-003-0356-x

DO - 10.1007/s00345-003-0356-x

M3 - Article

C2 - 12961097

AN - SCOPUS:1542293746

VL - 21

SP - 200

EP - 208

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -